Department of Medicine, School of Medicine, University of Virginia, Charlottesville, VA 22903, USA.
Division of Gastroenterology & Hepatology, School of Medicine, University of Virginia, Charlottesville, VA 22903, USA.
Int J Mol Sci. 2024 May 27;25(11):5807. doi: 10.3390/ijms25115807.
The renin-angiotensin system (RAS) is a complex homeostatic entity with multiorgan systemic and local effects. Traditionally, RAS works in conjunction with the kidney to control effective arterial circulation, systemic vascular resistance, and electrolyte balance. However, chronic hepatic injury and resulting splanchnic dilation may disrupt this delicate balance. The role of RAS in liver disease, however, is even more extensive, modulating hepatic fibrosis and portal hypertension. Recognition of an alternative RAS pathway in the past few decades has changed our understanding of RAS in liver disease, and the concept of opposing vs. "rebalanced" forces is an ongoing focus of research. Whether RAS inhibition is beneficial in patients with chronic liver disease appears to be context-dependent, but further study is needed to optimize clinical management and reduce organ-specific morbidity and mortality. This review presents the current understanding of RAS in liver disease, acknowledges areas of uncertainty, and describes potential areas of future investigation.
肾素-血管紧张素系统(RAS)是一个具有多器官系统和局部作用的复杂内稳态实体。传统上,RAS 与肾脏协同作用,控制有效动脉循环、全身血管阻力和电解质平衡。然而,慢性肝损伤和由此导致的内脏扩张可能会破坏这种微妙的平衡。然而,RAS 在肝病中的作用更为广泛,调节肝纤维化和门静脉高压。在过去几十年中对 RAS 替代途径的认识改变了我们对肝病中 RAS 的理解,“对立”与“再平衡”力量的概念是当前研究的重点。RAS 抑制在慢性肝病患者中是否有益似乎取决于具体情况,但需要进一步研究来优化临床管理并降低器官特异性发病率和死亡率。本文综述了目前对肝病中 RAS 的认识,承认了存在不确定性的领域,并描述了未来可能的研究领域。